Nicox Completes NCX 470 New Drug Application Key Data Generation for Submission as Planned in H1 2026 All clinical trial and long-term stability data required for the preparation of the New Drug ...

Acquisition provides Virbac with a leading specialty product, in a growing segment, to improve the quality of life for senior cats.

Nicox finalise la génération des données clés de demande d’autorisation de mise sur le marché de NCX 470 pour un dépôt maintenu au premier semestre 2026 Toutes les données d’ essais cliniques et de ...

Cette acquisition apporte à Virbac un produit de spécialité de premier plan, sur un segment en croissance, pour améliorer la qualité de vie des chats âgés.

The evoBrix® X modular Medicaid Enterprise System (MES) platform that enables states to deploy new systems with greater speed and efficiency while maintaining the governance and compliance standards ...

Six years later, an 80-year-old woman stepped into Dr. Steele’s clinic with anxiety, depression, high blood pressure, arthritis, and a fresh dementia diagnosis. Though he had never treated dementia, ...

Findings provide scientific insights into the contributions of IDO1 and PD-L1 vaccination to PD-1 blockade for the treatment of metastatic melanoma; Five-year analysis of median p ...

Allogene’s investigational AlloCAR T oncology products utilize Cellectis technologies. Cemacabtagene ansegedleucel (cema-cel) was developed based on an exclusive license granted by Cellectis to ...

Following a thorough review process conducted with the assistance of its legal and financial advisors, Generation Bio’s board of directors has determined that the acquisition by XOMA Royalty is in the ...

On November 25, 2025, Claret European Growth Capital Fund III SCSp converted its portion of the Tranche A convertible OCABSA resulting in the issuance of 392,695 ordinary shares of the Company.

Vivos management will discuss the strategic business model pivot and operational execution; the market opportunity and competitive environment; and Vivos’ growth and financial strategies. To register ...

The securities described above will be offered by Kyverna pursuant to an effective “shelf” registration statement on Form S-3 (File No. 333-286180) that was filed with the Securities and Exchange ...